CAS: 120964-45-6; (1S,2R,5R)-5-(4-Amino-1H-Imidazo[4,5-C]Pyridin-1-yl)-3-(Hydroxymethyl)Cyclopent-3-Ene-1,2-Diol Hydrochloride

结构式图片

上下游产品

-4,5-O-isopropylidene-2-cyclopenten-1-ol methanesulfonate(1S,4R,5S)-(-)-3-(benzyloxy)methyl-4,5-O-isopropylidene-2-cyclopenten-1-ol methanesulfonate 4-chloro-1H-imidazo[4,5-c]pyridine -4-chloroimidazopyridine(-)-1-(1R,4R,5S)-3-(Hydroxymethyl)-4,5-dihydroxy-2-cyclopenten-1-yl-4-chloroimidazo4,5-cpyridine -4-chloroimidazopyridine(-)-1-(1R,4R,5S)-3-(Benzyloxymethyl)-4,5-O-isopropylidene-2-cyclopenten-1-yl-4-chloroimidazo4,5-cpyridine

合成工艺路线路线简述

    📜1-[(3Ar,6R,6As)-2,3A-Dimethyl-4-(Phenylmethoxymethyl)-6,6A-Dihydrocyclopenta[d][1,3]Dioxol-6-Yl]-4-Chloroimidazo[4,5-C]Pyridine 反应生成3-去氮腺嘌呤a
    参考文献:Tseng,Christopher K. H.;Marquez,Victor E.;Fuller,Richard W.;Goldstein,+,J. Med. Chem.,32,(1989) N,C. 1442-1446
    标题:Tseng,Christopher K. H.;Marquez,Victor E.;Fuller,Richard W.;Goldstein,+,J. Med. Chem.,32,(1989) N,C. 1442-1446

    海关参考信息

    专利信息


    专利号:US-2009270431-A1
    优先权日:2005-10-19
    标 题 :Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections
    发明人:CHU DAVID C K; CHO JONG HYUN; KIM HYO-JOONG
    权利人:UNIV GEORGIA RES FOUND
    摘要:The present invention relates to compounds according to the structure (I), Where B is formula (Ia), formula (Ib) or formula (Ic); A is H, OR 2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A′ is H, OR2 or halogen (F, Cl, Br, I, preferably F or Br, more preferably F); A″ is H or OR 1 , with the proviso that when A′ is OR, A is H; and when A is OR 2 , A′ is H; X is C—R 3 or N; Y is C—R 3 or N; preferably X or Y is N and X and Y are not both simultaneously N; R 3 is H or C 1 -C 3 alkyl; D is H or NHR 2 ; E is absent or H; G is O or NHR 2 ; J is N or C—R 4 ; K is N or C—H; R 4 is H, halogen (F, Cl, Br, I), CN, —C(â•?O)NH 2 , NH 2 , NO 2 , —Câ•?C—H (cis or trans) or —C≡C—H; R a is H or CH 3 ; Each R 1 is independently H, an acyl group, a C 1 -C 20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group; Each R 2 is independently H, an acyl group, a C 1 -C 20 alkyl or ether group;and Pharmaceutically acceptable salts, solvates or polymorphs thereof.

    专利号:WO-2007047793-A2
    优先权日:2005-10-19
    标 题 :Cyclopentenol nucleoside compounds, intermediates for their synthesis and methods of treating viral infections

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Tanaka R, Donovan N, Yu Q, Irie R, Hoon DS. Tumor Necrosis Factor-Alpha and Apoptosis Induction in Melanoma Cells through Histone Modification by 3-Deazaneplanocin A. J Invest Dermatol. 2013 Nov 13. doi: 10.1038/jid.2013.489. [Epub ahead of print] doi: 10.1002/asia.201300303. Epub 2013 Jun 7. doi: 10.1016/j.jchromb.2013.01.003. Epub 2013 Jan 9.
    5: Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43. doi: 10.1016/j.lungcan.2012.08.003. Epub 2012 Aug 25.
    6: Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, Voorhoeve PM, Yu Q, Tan PH, Bay BH, Itahana K, Tan P. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res. 2012 Aug 1;18(15):4201-12. doi: 10.1158/1078-0432.CCR-12-0036. Epub 2012 Jun 6. doi: 10.1158/1535-7163.MCT-12-0037. Epub 2012 May 23.

    合成参考文献


    参考文献:10.1186/s13148-021-01037-1
    摘要:Dominici C, Sgarioto N, Yu Z, Sesma-Sanz L, Masson J, Richard S, Raynal NJ-. Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells. Clinical Epigenetics. 2021 Mar 10;13(1):54. doi: 10.1186/s13148-021-01037-1.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知